Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.18
+0.24 (2.01%)
At close: Dec 5, 2025, 4:00 PM EST
11.94
-0.24 (-1.97%)
After-hours: Dec 5, 2025, 7:51 PM EST
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 12.67, with a low estimate of 11 and a high estimate of 14. The average target predicts an increase of 4.02% from the current stock price of 12.18.
Analyst Consensus: Buy
* Price targets were last updated on Oct 31, 2025.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | +6.73% | Oct 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +14.94% | Sep 16, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | -9.69% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | -1.48% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | -9.69% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
3.07B
from 2.79B
Increased by 9.99%
Revenue Next Year
3.28B
from 3.07B
Increased by 6.67%
EPS This Year
0.82
from -0.38
EPS Next Year
0.96
from 0.82
Increased by 17.81%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.4B | |
| Avg | 3.1B | 3.3B | |
| Low | 2.9B | 3.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.7% | 10.3% | |
| Avg | 10.0% | 6.7% | |
| Low | 5.0% | 1.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.86 | 1.08 | |
| Avg | 0.82 | 0.96 | |
| Low | 0.76 | 0.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 32.5% | |
| Avg | - | 17.8% | |
| Low | - | 6.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.